By Scientia Professor Vlado Perkovic

Journal articles

Perkovic V; Bakris GL; Blais J; Cherney D; Damaraju C; Gogate J; Heerspink HJL; Kosiborod M; Mahaffey KW, 2020, 'Risk of Hospitalization for Heart Failure (HHF) by eGFR and Urinary Albumin-to-Creatinine Ratio (UACR): Pooled Analyses from the CANVAS Program and CREDENCE', Journal of the American Society of Nephrology, 31, pp. 335 - 335, http://dx.doi.org/10.1681/asn.20203110s1335c

Jardine M; Zhou Z; Heerspink HJL; Li Q; Agarwal R; Bakris G; Charytan DM; Oh R; Pollock C; Wheeler DC; Zeeuw DD; Zhang H; Zinman B; Mahaffey KW; Perkovic V, 2020, 'SAT-156 RENAL, CARDIOVASCULAR, AND SAFETY OUTCOMES OF CANAGLIFLOZIN ACCORDING TO BASELINE ALBUMINURIA: A CREDENCE SECONDARY ANALYSIS', Kidney International Reports, 5, pp. S67 - S67, http://dx.doi.org/10.1016/j.ekir.2020.02.166

Liyanage T; Toyama T; Ninomiya T; Perkovic V; Woodward M; Fukagawa M; Matsushita K; Praditpornsilpa K; Seong HL; Iseki K; Lin MY; Stirnadel-Farrant HA; Jha V; Jun M, 2020, 'SUN-107 THE PREVALENCE OF CHRONIC KIDNEY DISEASE IN ASIA – A SYSTEMATIC REVIEW AND ANALYSIS', Kidney International Reports, 5, pp. S245 - S245, http://dx.doi.org/10.1016/j.ekir.2020.02.634

OSHIMA M; Wong MG; Hara A; Toyama T; Jun M; Jardine M; Pollock C; Woodward M; Chalmers J; Perkovic V; Wada T, 2020, 'SUN-161 CIRCULATING AUTOANTIBODIES TO ERYTHROPOIETIN RECEPTOR AND KIDNEY DISEASE PROGRESSION IN TYPE 2 DIABETES MELLITUS: RESULTS FROM THE ADVANCE STUDIES', Kidney International Reports, 5, pp. S267 - S267, http://dx.doi.org/10.1016/j.ekir.2020.02.690

Tiku A; Pascoe E; Boudville N; Cass A; Dalbeth N; Day RO; de Zoysa J; Douglas B; Faull R; Harris D; Hawley C; Jones GR; Kanellis J; Palmer S; Perkovic V; Rangan G; Reidlinger D; Robison L; Walker RJ; Walters G; Johnson DW; Badve S, 2020, 'The Effects of Allopurinol on the Progression of CKD According to Baseline Kidney Function: Prespecified Analyses of the CKD-FIX Trial', Journal of the American Society of Nephrology, 31, pp. 228 - 229, http://dx.doi.org/10.1681/asn.20203110s1228d

Tiku A; Pascoe E; Boudville N; Cass A; Dalbeth N; Day RO; de Zoysa J; Douglas B; Faull R; Harris D; Hawley C; Jones GR; Kanellis J; Palmer S; Perkovic V; Rangan G; Reidlinger D; Robison L; Walker RJ; Walters G; Johnson DW; Badve S, 2020, 'The Effects of Allopurinol on the Progression of CKD According to Baseline Serum Urate Level: Results from Post Hoc Analyses of the CKD-FIX Trial', Journal of the American Society of Nephrology, 31, pp. 223 - 223, http://dx.doi.org/10.1681/asn.20203110s1223a

Arnott C; Li J-W; Cannon CP; Neuen B; Heerspink HL; Neal B; Charytan DM; Agarwal R; Bakris GL; De Zeeuw D; Greene T; Levin A; Pollock C; Chang T; Rosenthal N; Zhang H; Zinman B; Perkovic V; Jardine M; Mahaffey K, 2020, 'THE EFFECTS OF CANAGLIFLOZIN ON HEART FAILURE AND CARDIOVASCULAR DEATH BY BASELINE PARTICIPANT CHARACTERISTICS: ANALYSIS OF THE CREDENCE TRIAL', Journal of the American College of Cardiology, 75, pp. 674, http://dx.doi.org/10.1016/s0735-1097(20)31301-2

Sen T; Li J; Neuen BL; Neal B; Parikh CR; Coca SG; Perkovic V; de Zeeuw D; Mahaffey KW; Hansen MK; Heerspink HJL, 2020, 'The SGLT2 Inhibitor Canagliflozin Reduces the Plasma Markers TNFR-1, TNFR-2, and KIM-1 in the CANVAS Trial', Journal of the American Society of Nephrology, 31, pp. 343 - 343, http://dx.doi.org/10.1681/asn.20203110s1343a

Smyth B; van den Broek-Best O; Hong D; Howard K; Rogers K; Zuo L; Gray NA; de Zoysa JR; Chan CT; Lin H; Zhang L; Xu J; Cass A; Gallagher M; Perkovic V; Jardine M, 2019, 'Varying association of extended hours dialysis with quality of life', Clinical Journal of the American Society of Nephrology, 14, pp. 1751 - 1762, http://dx.doi.org/10.2215/CJN.06800619

Li JW; Badve SV; Zhou Z; Rodgers A; Day R; Oh R; Lee M; Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Matthews DR; Neal B, 2019, 'The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program', The Lancet Rheumatology, 1, pp. e220 - e228, http://dx.doi.org/10.1016/S2665-9913(19)30078-5

Smyth B; Trongtrakul K; Haber A; Talbot B; Hawley C; Perkovic V; Woodward M; Jardine M, 2019, 'Inequities in the global representation of sites participating in large, multicentre dialysis trials: A systematic review', BMJ Global Health, 4, pp. e001940, http://dx.doi.org/10.1136/bmjgh-2019-001940

Neuen BL; Young T; Heerspink HJL; Neal B; Perkovic V; Billot L; Mahaffey KW; Charytan DM; Wheeler DC; Arnott C; Bompoint S; Levin A; Jardine MJ, 2019, 'SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis', The Lancet Diabetes and Endocrinology, 7, pp. 845 - 854, http://dx.doi.org/10.1016/S2213-8587(19)30256-6

Oshima M; Jun M; Ohkuma T; Toyama T; Wada T; Cooper ME; Hadjadj S; Hamet P; Harrap S; Mancia G; Marre M; Williams B; Chalmers J; Woodward M; Perkovic V, 2019, 'The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study', Diabetologia, 62, pp. 1988 - 1997, http://dx.doi.org/10.1007/s00125-019-4948-4

Neuen BL; Cherney DZ; Jardine MJ; Perkovic V, 2019, 'Sodium-glucose cotransporter inhibitors in type 2 diabetes: Thinking beyond glucose lowering', CMAJ, 191, pp. E1128 - E1135, http://dx.doi.org/10.1503/cmaj.190047

Perkovic V, 2019, 'Blood pressure: at what level is treatment worthwhile? (vol 42, pg 127, 2019)', AUSTRALIAN PRESCRIBER, 42, pp. 175 - 175, http://dx.doi.org/10.18773/austprescr.2019.062

Zhou Z; Jardine M; Perkovic V; Matthews DR; Mahaffey KW; de Zeeuw D; Fulcher G; Desai M; Oh R; Simpson R; Watts NB; Neal B, 2019, 'Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program', Diabetologia, 62, pp. 1854 - 1867, http://dx.doi.org/10.1007/s00125-019-4955-5

Marx N; McGuire DK; Johansen O; Rosenstock J; Kahn SE; Cooper ME; Toto R; Wanner C; Pfarr E; Schnaidt SY; George JT; Von Eynatten M; Perkovic V; Zinman B; Alexander JA, 2019, 'P6272First plus recurrent CV and hospitalization events in the CArdiovascular and Renal Microvascular outcomE study with LINAgliptin (CARMELINA) in patients with type 2 diabetes and cardiorenal disease', European Heart Journal, 40, http://dx.doi.org/10.1093/eurheartj/ehz746.0871

Gray NA; Zuo L; Hong D; Smyth B; Jun M; De Zoysa J; Vo K; Howard K; Wang J; Lu C; Liu Z; Cass A; Perkovic V; Jardine M, 2019, 'Quality of life in caregivers compared with dialysis recipients: The Co-ACTIVE sub-study of the ACTIVE dialysis trial', Nephrology, 24, pp. 1056 - 1063, http://dx.doi.org/10.1111/nep.13530

Smyth B; Haber A; Trongtrakul K; Hawley C; Perkovic V; Woodward M; Jardine M, 2019, 'Representativeness of Randomized Clinical Trial Cohorts in End-stage Kidney Disease: A Meta-analysis', JAMA Internal Medicine, 179, pp. 1316 - 1324, http://dx.doi.org/10.1001/jamainternmed.2019.1501

Jardine MJ; Mahaffey KW; Perkovic V, 2019, 'Canagliflozin and Renal Outcomes in Diabetic Nephropathy. Reply', The New England journal of medicine, 381, pp. 1089 - 1090, http://dx.doi.org/10.1056/NEJMc1909687

Inker LA; Heerspink HJL; Tighiouart H; Levey AS; Coresh J; Gansevoort RT; Simon AL; Ying J; Beck GJ; Wanner C; Floege J; Li PKT; Perkovic V; Vonesh EF; Greene T, 2019, 'GFR slope as a surrogate end point for kidney disease progression in clinical trials: A meta-analysis of treatment effects of randomized controlled trials', Journal of the American Society of Nephrology, 30, pp. 1735 - 1745, http://dx.doi.org/10.1681/ASN.2019010007

Mahaffey KW; Jardine MJ; Bompoint S; Cannon CP; Neal B; Heerspink HJL; Charytan DM; Edwards R; Agarwal R; Bakris G; Bull S; Capuano G; De Zeeuw D; Greene T; Levin A; Pollock C; Sun T; Wheeler DC; Yavin Y; Zhang H; Zinman B; Rosenthal N; Brenner BM; Perkovic V, 2019, 'Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial', Circulation, 140, pp. 739 - 750, http://dx.doi.org/10.1161/CIRCULATIONAHA.119.042007

Ha JT; Neuen BL; Cheng LP; Jun M; Toyama T; Gallagher MP; Jardine MJ; Sood MM; Garg AX; Palmer SC; Mark PB; Wheeler DC; Jha V; Freedman B; Johnson DW; Perkovic V; Badve SV, 2019, 'Benefits and harms of oral anticoagulant therapy in chronic kidney disease', Annals of Internal Medicine, 171, pp. 181 - 189, http://dx.doi.org/10.7326/M19-0087

Atkins ER; Perkovic V, 2019, 'Blood pressure: At what level is treatment worthwhile?', Australian Prescriber, 42, pp. 127 - 130, http://dx.doi.org/10.18773/austprescr.2019.038

Perkovic V, 2019, 'SGLT2 inhibitor lowers risk of kidney failure in type 2diabetes', Pharmaceutical Journal, 303, http://dx.doi.org/10.1211/PJ.2019.20206795

Verma S; Mazer CD; Perkovic V, 2019, 'Is it time to REWIND the cardiorenal clock in diabetes?', The Lancet, 394, pp. 95 - 97, http://dx.doi.org/10.1016/S0140-6736(19)31267-X

Zhan Z; Smyth B; Toussaint ND; Gray NA; Zuo L; De Zoysa JR; Chan CT; Jin C; Scaria A; Hawley CM; Perkovic V; Jardine MJ; Zhang L, 2019, 'Effect of extended hours dialysis on markers of chronic kidney disease-mineral and bone disorder in the ACTIVE Dialysis study', BMC Nephrology, 20, pp. 258, http://dx.doi.org/10.1186/s12882-019-1438-3

Jardine MJ; Li N; Ninomiya T; Feng X; Zhang J; Shi J; Zhang Y; Zhang R; Zhang J; Hao J; Perkovic V; Heerspink HL; Wu Y; Yan LL; Neal B, 2019, 'Dietary Sodium Reduction Reduces Albuminuria: A Cluster Randomized Trial', Journal of Renal Nutrition, 29, pp. 276 - 284, http://dx.doi.org/10.1053/j.jrn.2018.10.009

Perkovic V; Jardine MJ; Neal B; Bompoint S; Heerspink HJL; Charytan DM; Edwards R; Agarwal R; Bakris G; Bull S; Cannon CP; Capuano G; Chu PL; De Zeeuw D; Greene T; Levin A; Pollock C; Wheeler DC; Yavin Y; Zhang H; Zinman B; Meininger G; Brenner BM; Mahaffey KW; Jha V, 2019, 'Canagliflozin and renal outcomes in type 2 diabetes and nephropathy', New England Journal of Medicine, 380, pp. 2295 - 2306, http://dx.doi.org/10.1056/NEJMoa1811744

Ohkuma T; Jun M; Chalmers J; Cooper ME; Hamet P; Harrap S; Zoungas S; Perkovic V; Woodward M, 2019, 'Combination of changes in estimated GFR and albuminuria and the risk of major clinical outcomes', Clinical Journal of the American Society of Nephrology, 14, pp. 862 - 872, http://dx.doi.org/10.2215/CJN.13391118

LI J; BADVE SV; ZHOU Z; OH R; LEE M; PERKOVIC V; ZEEUW DD; MAHAFFEY KW; FULCHER G; MATTHEWS DR; NEAL B, 2019, '1216-P: The Effects of Canagliflozin on Uric Acid and Gout in Patients with Type 2 Diabetes in the CANVAS Program', Diabetes, 68, http://dx.doi.org/10.2337/db19-1216-p

Marx N; Mcguire DK; Johansen OE; Rosenstock J; Kahn SE; Cooper ME; Toto RD; Wanner C; Pfarr E; Schnaidt S; George J; Von Eynatten M; Perkovic V; Zinman B; Alexander JH, 2019, 'Analyses of First plus Recurrent Cardiovascular and Hospitalization Events in the Cardiovascular and Renal Microvascular Outcome Study with Linagliptin (CARMELINA) in Patients with Type 2 Diabetes and Cardiorenal Disease', DIABETES, 68, http://dx.doi.org/10.2337/db19-432-P

MATTHEWS DR; WYSHAM CH; DAVIES MJ; SLEE A; ALBA M; LEE M; CAPUANO G; PERKOVIC V; MAHAFFEY KW; NEAL B, 2019, 'Effects of Canagliflozin (CANA) on Initiation of Insulin in CANVAS Program', Diabetes, 68, http://dx.doi.org/10.2337/db19-1206-p

Matthews DR; Li Q; Perkovic V; Mahaffey KW; de Zeeuw D; Fulcher G; Desai M; Hiatt WR; Nehler M; Fabbrini E; Kavalam M; Lee M; Neal B, 2019, 'Effects of canagliflozin on amputation risk in type 2 diabetes: The CANVAS Program', Diabetologia, 62, pp. 926 - 938, http://dx.doi.org/10.1007/s00125-019-4839-8

Perkovic V; Bain S; Bakris G; Buse J; Gondolf T; Idorn T; Lausvig N; Mahaffey K; Marso S; Nauck M; Pratley R; Rossing P; Zinman B; Mann J, 2019, 'FP482EGFR LOSS WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUE TREATMENT: DATA FROM SUSTAIN 6 AND LEADER', Nephrology Dialysis Transplantation, 34, http://dx.doi.org/10.1093/ndt/gfz106.fp482

Perkovic V; Bain S; Bakris G; Buse J; Idorn T; Mahaffey K; Marso S; Nauck M; Pratley R; Rasmussen S; Rossing P; Tornoe K; Zinman B; Mann J, 2019, 'FP483EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) – A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER', Nephrology Dialysis Transplantation, 34, http://dx.doi.org/10.1093/ndt/gfz106.fp483

Oshima M; Ohkuma T; Neal B; Li Q; De Zeeuw D; Mahaffey KW; Fulcher G; Canovatchel W; Matthews DR; Perkovic V; Li Q, 2019, 'FP484DIFFERENT eGFR THRESHOLDS AND THE RENAL EFFECTS OF CANAGLIFLOZIN: DATA FROM THE CANVAS PROGRAM', Nephrology Dialysis Transplantation, 34, pp. gfz106.fp484, http://dx.doi.org/10.1093/ndt/gfz106.fp484

Cooper ME; Perkovic V; Groop PH; Hocher B; Hehnke U; Meinicke T; Koitka-Weber A; Van Der Walt S; Von Eynatten M, 2019, 'Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptinwith renin-angiotensin system inhibitors in type 2 diabetic patientswith albuminuria', Journal of Hypertension, 37, pp. 1294 - 1300, http://dx.doi.org/10.1097/HJH.0000000000002032

Rosenstock J; Kahn SE; Johansen OE; Cooper ME; Marx N; Alexander JH; Toto RD; Wanner C; Pfarr E; Schnaidt S; George J; Von Eynatten M; Mcguire DK; Perkovic V; Zinman B, 2019, 'Interrelationship between Hypoglycemia and CV and Mortality Outcomes in Type 2 Diabetes in the CARMELINA Trial', DIABETES, 68, http://dx.doi.org/10.2337/db19-388-P

Perkovic V; Bain S; Bakris G; Buse J; Idorn T; Mahaffey K; Marso S; Nauck M; Pratley R; Rasmussen S; Rossing P; Tornoe K; Zinman B; Mann J, 2019, 'SaO010EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES – A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS', Nephrology Dialysis Transplantation, 34, http://dx.doi.org/10.1093/ndt/gfz101.sao010

Figtree GA; Rådholm K; Barrett TD; Perkovic V; Mahaffey KW; De Zeeuw D; Fulcher G; Matthews DR; Shaw W; Neal B, 2019, 'Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus: Results From the CANVAS Program', Circulation, 139, pp. 2591 - 2593, http://dx.doi.org/10.1161/CIRCULATIONAHA.119.040057

Heerspink HJL; Parving HH; Andress DL; Bakris G; Correa-Rotter R; Hou FF; Kitzman DW; Kohan D; Makino H; McMurray JJV; Melnick JZ; Miller MG; Pergola PE; Perkovic V; Tobe S; Yi T; Wigderson M; de Zeeuw D; Elbert A; Vallejos A; Alvarisqueta A; Maffei L; Juncos L; de Arteaga J; Greloni G; Farias E; Zucchini A; Vogel D; Cusumano A; Santos J; Fraenkel M; Gallagher M; Davis T; Acharya S; Cooke D; Suranyi M; Roger S; Toussaint N; Pollock C; Chan D; Stranks S; MacIsaac R; Endre Z; Schmidt A; Prager R; Mayer G; Warling X; Jadoul M; Hougardy J; Vercammen C; Van Vlem B; Gillard P; Costa e Forti A; Borges JL; Santos Canani L; Eliaschewitz F; Leite S; Fraige Filho F; Paschoalin R; Moura Neto JA; Deboni L; de Lourdes Noronha I; Cercato C; Prompt CA; Zanella M; Rassi N; D'Avila D; Milagres R; Felicio J; Pecoits Filho R; Riella MC; Salles J; Keitel E; Draibe S; Amodeo C; Youmbissi J; Roy L; Cournoyer S; Jolly S; Pichette V; Nesrallah G; Bajaj HS; Khandwala H; Aronson R; Goluch R; Tam P; Rabbat C; Bailey G; Chow S; Castillo A; Danin Vargas A; Gonzalez F; Munoz R; Gutierrez V; Godoy G; Zhao H; Liu Z; Zhao M; Guo X; Su B, 2019, 'Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial', The Lancet, 393, pp. 1937 - 1947, http://dx.doi.org/10.1016/S0140-6736(19)30772-X

Cheung AK; Chang TI; Cushman WC; Furth SL; Ix JH; Pecoits-Filho R; Perkovic V; Sarnak MJ; Tobe SW; Tomson CRV; Cheung M; Wheeler DC; Winkelmayer WC; Mann JFE; Bakris GL; Damasceno A; Dwyer JP; Fried LF; Haynes R; Hirawa N; Holdaas H; Ibrahim HN; Ingelfinger JR; Iseki K; Khwaja A; Kimmel PL; Kovesdy CP; Ku E; Lerma EV; Luft FC; Lv J; McFadden CB; Muntner P; Myers MG; Navaneethan SD; Parati G; Peixoto AJ; Prasad R; Rahman M; Rocco MV; Rodrigues CIS; Roger SD; Stergiou GS; Tomlinson LA; Tonelli M; Toto RD; Tsukamoto Y; Walker R; Wang AYM; Wang J; Warady BA; Whelton PK; Williamson JD, 2019, 'Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference', Kidney International, 95, pp. 1027 - 1036, http://dx.doi.org/10.1016/j.kint.2018.12.025

Toyama T; Neuen BL; Jun M; Ohkuma T; Neal B; Jardine MJ; Heerspink HL; Wong MG; Ninomiya T; Wada T; Perkovic V, 2019, 'Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis', Diabetes, Obesity and Metabolism, 21, pp. 1237 - 1250, http://dx.doi.org/10.1111/dom.13648

Rahimi K; Canoy D; Nazarzadeh M; Salimi-Khorshidi G; Woodward M; Teo K; Davis BR; Chalmers J; Pepine CJ; Chalmers J; Perkovic V; Sundstorm J, 2019, 'Investigating the stratified efficacy and safety of pharmacological blood pressure-lowering: An overall protocol for individual patient-level data meta-analyses of over 300 000 randomised participants in the new phase of the Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTTC)', BMJ Open, 9, pp. e028698, http://dx.doi.org/10.1136/bmjopen-2018-028698

Kahn S; Perkovic V; Johansen OE; Rosenstock J; McGuire D; Toto R; Nikolaus M; Alexander J; Zinman B; Pfarr E; Schnaidt S; Meinicke T; George J; von Eynatten M; Cooper M; Wanner C, 2019, 'SUN-LB015 Baseline Characteristics and Effects on CV and Kidney Outcomes with Linagliptin Versus Placebo, Across GFR Categories in CARMELINA', Journal of the Endocrine Society, 3, http://dx.doi.org/10.1210/js.2019-sun-lb015

Liao JL; van den Broek-Best O; Smyth B; Hong D; Vo K; Zuo L; Gray NA; Chan CT; de Zoysa J; Perkovic V; Jiang L; Jardine M, 2019, 'Effect of extended hours dialysis on sleep quality in a randomized trial', Nephrology, 24, pp. 430 - 437, http://dx.doi.org/10.1111/nep.13236

Thompson A; Carroll K; Inker LA; Floege J; Perkovic V; Boyer-Suavet S; Major RW; Schimpf JI; Barratt J; Cattran DC; Gillespie BS; Kausz A; Mercer AW; Reich HN; Rovin BH; West M; Nachman PH, 2019, 'Proteinuria reduction as a surrogate end point in trials of IgA nephropathy', Clinical Journal of the American Society of Nephrology, 14, pp. 469 - 481, http://dx.doi.org/10.2215/CJN.08600718

Garg AX; Chan MTV; Cuerden MS; Devereaux PJ; Abbasi SH; Hildebrand A; Lamontagne F; Lamy A; Noiseux N; Parikh CR; Perkovic V; Quantz M; Rochon A; Royse A; Sessler DI; Shah PJ; Sontrop JM; Tagarakis GI; Teoh KH; Vincent J; Walsh M; Yared JP; Yusuf S; Whitlock RP, 2019, 'Effect of methylprednisolone on acute kidney injury in patients undergoing cardiac surgery with a cardiopulmonary bypass pump: A randomized controlled trial', CMAJ, 191, pp. E247 - E256, http://dx.doi.org/10.1503/cmaj.181644

Zhang L; Zuo L; Yu F; Wang H; Bai K; Chen R; Chu H; Gan L; Gao B; Zhao M-H; Wang Y; Zhang H; He X; Liu L; Long J; Shi Y; Su Z; Sun X; Tang W; Wang F; Wang J; Wang S; Wang Y; Yang C; Yu F; Zhang D; Zhang H; Zhao M; Zhao X; Zheng L; Zhou Z; Coresh J; Jayne D; Levey A; Perkovic V; Saran R; Feldman H; Jha V; Levin A; Ronco P; Tang S; Chen M; Fu P; Li G; Liang X; Lin H; Liu Z; Ding J; Li D; Li S; Liao Y; Liu J; Ma Y; Yu X-Q; Hong C, 2019, 'China Kidney Disease Network (CK-NET) 2015 Annual Data Report', KIDNEY INTERNATIONAL SUPPLEMENTS, 9, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000459228200001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Back to profile page